TRASTUZUMAB DERUXTECAN

Brand name:

• Enhertu®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Early Resolution Pathway)

Comment:

--

Submission sponsor:

AstraZeneca Pty Ltd

Other PBAC consideration:

• TRASTUZUMAB DERUXTECAN
• TRASTUZUMAB DERUXTECAN
• TRASTUZUMAB DERUXTECAN

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

06/04/2023

Lodgement of required documentation:

13/04/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 15/06/2023

Status:

Finalised

Government processes:

Commenced on 14/07/2023

Medicine listed on the PBS:

01/11/2023 (see PBS schedule)

---